The startup, founded just last year and a JLABS alumnus, is working on next-gen tech.
HiFiBiO Therapeutics has had a busy year, as pacts and raises abound, and it’s showing no signs of slowing down as it gets its checkbook out for an unusual…
An FDA advisory committee recommended AcelRx's Dsuvia, a sublingual version of sufentanil, for approval in a 10-3 vote.
The revised deal sets Roche up to work with SQZ on antigen-presenting cells designed to trigger killer T cell attacks against tumors.
Scientists have demonstrated how mutations in cell proteins known as “splicing factors” can cause the eye disease retinitis pigmentosa.
DFCI's Haining to become VP, Oncology at Merck; Pfizer poaches Quest exec to spearhead digital; and Perrigo swaps CEO for former tobacco executive.
The reverse merger comes six months after Adynxx committed to advancing pain drug brivoligide, despite the candidate coming up short in phase 2.
The tiny offering will equip Hoth to test a topical formulation of the broad-spectrum antibiotic gentamicin in a phase 2 eczema trial.
In our EuroBiotech roundup this week, FDA hits Acacia with CRL, Therachon buys GLyPharma and Oryzon starts phase 2a trial.
In this week's EuroBiotech Report, EU funding is on track for new highs, Orchard plans a $173 million IPO, Sitryx raises $30 million and more.